Slides
Page 1
FY26 Results Investor Presentation August 2026 PHARMX TECHNOLOGIES LIMITED (ASX:PHX)
Page 2
This presentation has been prepared by Pharmx Technologies Limited (Pharmx or the Company or PHX) . It should not be considered as an offer or invitation to subscribe for, or purchase any shares in PHX, or as an inducement to purchase any shares in Pharmx . No agreement to subscribe for securities in Pharmx will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation . This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction . It has been prepared for information purposes only . This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor . It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice . This presentation may contain forward - looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties . These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place . Such forward - looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management . Although the Company believes that the expectations reflected in the forward - looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward - looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making . Readers are cautioned not to place undue reliance on these forward - looking statements . Except to the extent required by law, the Company has no intention to update or revise forward - looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation . Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information . To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation . Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation . NOTICE & DISCLAIMER
Page 3
Dominant Position PHARMX OVERVIEW Critical industry infrastructure
Page 4
WHERE WE ARE NOW One platform solution, leveraging a common data set 01 EDI · Pharmx Gateway Subscription or per - account fees 02 Marketplace Invoice - linked revenues 03 Data & Analytics Subscription + usage fees SUMMARY Single Platform differentiates Gateway services, powers Marketplace and drives the Analytics and customer value flywheel.
Page 5
FY26 HIGHLIGHTS Financial update $7.74m, 3% above FY25 . Positive result in line with expectations. Underpinned by strong platform growth in line with strategy. FY26 8 % ▲ Gateway Revenue Gateway recurring revenue increase compared to FY25 (1) FY26 73 % ▲ Marketplace Revenue Increase in marketplace recurring revenue compared to FY25 FY26 84 % ▲ Gross Margin 2% improvement on FY25 FY26 $1.1 m ▲ Positive EBITDA $0.5m decrease compared with FY25 JUNE 2026 $2.6 m ▲ Strong Cash position (1) FY26 67 % ▲ NZ Revenue Increase in New Zealand recurring revenue compared to FY25
Page 6
FY26 RESULTS Profit & loss FY26 set strong foundations for growth $'000 FY26 FY25 Change Var % Revenue 7,737 7,530 207 3% Operating costs (6,657) (5,922) (735) (12)% EBITDA 1,080 1,608 (528) (33)% Depreciation, Amortisation, Interest & Share - based payments (2,767) (1,529) (1,238) (81)% PBT (1,687) 79 (1,766) (2,235)% Tax (139) (343) 204 (59)% NPAT (1,826) (264) (1,562) (592)% COMMENTARY
Page 7
FY26 RESULTS Positive Operating Cashflow $'000 FY26 FY25 Change Var % Receipts from customers - continuing operations 8,444 8,089 355 4% Statutory operating cashflow 825 (8,133) 8,958 (110)% Pharmx legal costs and court proceeds - 9,898 (9,898) (100)% Underlying operating cashflow incl. net R&D benefit 825 1,765 (940) (53)% Less net R&D incentive received (368) (863) 495 (57)% Underlying operating cashflow excl. net R&D benefit 457 902 (445) (49)% Net cash used in investing activities (2,104) (695) (1,409) (203)% Net cash used in financing activities (322) (136) (186) (137)% Closing cash balance 2,571 4,172 (1,601) (38)% COMMENTARY
Page 8
FY26 HIGHLIGHTS Growing value delivery and strong strategy execution VOLUME GROWTH 11 % ▲ Total GTV 11 % ▲ Number of Orders 20 % ▲ Volume based ARR ARPU +10 % ▲ ARPU, Gateway +69 % ▲ ARPU, Marketplace +12 % ▲ ARPU, Analytics Supplier migration 13% improvement YoY in transition of suppliers to Single Platform SUPPLIER TRANSITION 13% improvement YoY in transition of suppliers to Single Platform 2026 115 · 64% 64 · 36% 2025 102 · 60% 68 · 40% SUMMARY Strong financial results are supported by excellent platform metrics displaying strong growth over the year.
Page 9
FY26 HIGHLIGHTS Scaling marketplace growth TARGET COHORT TOTAL Growth in Active Users +200% +57% Monthly Repeat Purchase Rate* 77% 49% Monthly Purchase Frequency* 17.7 7.6 Growth in Total GTV +340% +261% Monthly spend per pharmacy* +71% +152% 304 % ▲ Marketplace GTV 108 % ▲ Number of Orders
Page 10
FY26 HIGHLIGHTS Foundations laid in FY26 expected to convert to growth in FY27 01 Launch of single platform and marketplace Strong FY26 performance is expected to increased scale in FY27. 02 Defining strategic alliance formed with Sigma Strong pipeline of strategically aligned initiatives coming online in FY27 03 Core EDI service modernization and vertical expansion New revenue lines and structural margin gain from FY27. 04 Supplier additions and migrations 05 Lower cost to serve and faster delivery cadence into FY27. 06 Strengthened leadership and AI deployment Key service partners expansion Contracted growth already secured for FY27 such as Boody, Pacific Optics, Kind Brands and Dedalus Lower cost to serve and faster delivery cadence into FY27.
Page 11
PHARMX OVERVIEW Favourable market trends support growth DEMOGRAPHICS & CHRONIC DISEASE TRENDS 15.4m AIHW / ABS, 2022 6.7m ABS Population Projections 1.9m Diabetes Australia, 2025 PHARMACY & MEDICINES MARKET GROWTH 335m AIHW / PBS, 2024 – 25 ~50% Fonto Market Metrics, 2025 $65.7b IMARC Group, 2025 RETAILISATION & CHANGING CONSUMERS 12.9% IMARC Group, 2025 ~20 Australasian Pharmacy / PSA, 2025 Under 35’s NIQ, 2025
Page 12
PHARMX FY27 FOCUS FY27 is a year of execution 01 Scale Marketplace $100m annualised GTV run rate 02 Expand margins +$200m GTV available to renew 03 EDI · modernise & vertically expand Expansion of suppliers (+40), focusing on AU and NZ 04 Maximise the Sigma alliance Anchor distribution across Australia’s largest pharmacy footprint 05 Data & analytics Partnership - led solutions. increasing data - as - a - service revenue New Zealand Supplier growth expands market exposure through Bargain Chemist and TONIQ, plus vertical integration in partnership with Sigma which becomes the base for further expansion.
Page 13
Q&A
Page 14
Appendix 14
Page 15
COMPANY SNAPSHOT Capital structure Capital Structure As at 20 August 2026 Ticker Share price (20 August 2026) Shares on issue Market cap (20 August 2026) Cash (30 June 2026) Debt Enterprise Value (20 August 2026) Performance rights Major Shareholders As at 20 August 2026 Entity name Shares % BNP Paribas Nominees Pty Ltd (Clearstream) 100.7m 15.12 BNP Paribas Nominees Pty Ltd (IB AU NOMS RetailClient) 76.5m 11.49 CW Retail Holdings 66.6m 10.00 Arrotex Investments Holding 1 60.0m 9.01 BNP Paribas Noms 33.6m 5.05 J P Morgan Nominees Australia 28.9m 4.34 HSBC Custody Nominees 28.6m 4.29 Mersault Pty Ltd 26.8m 4.02 HSBC Custody Nominees 19.1m 2.87 Mr David Gerald Manuel 14.7m 2.20 Top 10 — Total 455.5m 68.4%
Page 16
FY26 FINANCIALS Profit & Loss $'000 FY26 FY25 Var $ Var % Revenue 7,737 7,530 207 3% Cost of sales (rebates) (1,272) (1,359) 87 (6)% Marketing (450) (347) (103) 30% Employee benefits (3,692) (3,509) (183) 5% Technology, communication and cloud costs (673) (536) (137) 26% Professional fees (846) (452) (394) 87% Other (51) (43) (8) 19% Research and development tax benefit 327 324 3 1% Total Expenses (6,657) (5,922) (735) 12% EBITDA 1,080 1,608 (528) (33)% Share based payments (1,165) (220) (945) 430% Depreciation, amortisation and finance costs (1,602) (1,309) (293) 22% Income tax expense (139) (343) 204 (59)% NPAT (1,826) (264) (1,562) 592%
Page 17
FY26 FINANCIALS Cash Flow $'000 FY26 FY25 Cash flows from operating activities Receipts from customers 8,444 8,089 Payments to suppliers and employees (8,107) (7,397) Payments for Pharmx court case judgement - (9,898) Interest and other revenue received 120 210 Research and development incentive received, net of income tax paid 368 863 Net cash from operating activities 825 (8,133) Cash flows from investing activities Payments for property, plant and equipment (20) (28) Payments for intangible assets (2,084) (1,723) Payments for security deposits - (199) Disposal of discontinued operations, net of cash disposed and transaction costs - 1,255 Net cash used in investing activities (2,104) (695) FY26 FY25 Cash flows from financing activities Share issue transaction costs (35) - Principal paid to lease liabilities (243) (121) Interest paid on lease liabilities (44) (15) Net cash from financing activities (322) (136) Net decrease in cash and cash equivalents (1,601) (8,964) Cash and cash equivalents at beginning of the period 4,172 13,136 Cash and cash equivalents at the end of the period 2,571 4,172
Page 18
FY26 FINANCIALS Balance Sheet $'000 30 Jun 2026 30 Jun 2025 Current assets Cash and cash equivalents 2,571 4,172 Trade and other receivables 1,894 1,117 Income tax receivable 904 368 Other assets 2,134 101 Total 7,503 5,758 Non - current assets Property, plant and equipment 37 32 Right of use assets 508 774 Intangibles 11,756 11,790 Deferred tax assets 184 165 Other Assets 7,282 306 Total 19,767 13,067 Total assets 27,270 18,825 30 Jun 2026 30 Jun 2025 Current Liabilities Trade and other payables 2,766 1,211 Provisions 183 137 Lease liability 275 354 Unearned revenue - 28 Total 3,224 1,730 Non - current liabilities 43 64 Provisions 265 540 Lease liability 457 563 Deferred Tax liability 765 1,167 Total Total liabilities Equity Issued capital 725 244 Reserves Accumulated losses 3,989 2,897 Net assets 23,281 15,928 102,668 93,970 (80,112) (78,286) 23,281 15,928 Total equity
Page 19
Thank you Level 7, 1 Castlereagh Street Sydney 2000 investor.relations@pharmx.com.au